Kalevi Kurkijarvi Sells 2,000 Shares of FibroGen Inc (FGEN) Stock

FibroGen Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $27.40, for a total value of $54,800.00. Following the completion of the transaction, the director now owns 36,000 shares in the company, valued at $986,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Kalevi Kurkijarvi also recently made the following trade(s):

  • On Monday, April 17th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $25.25, for a total value of $50,500.00.
  • On Thursday, February 16th, Kalevi Kurkijarvi sold 2,000 shares of FibroGen stock. The stock was sold at an average price of $24.45, for a total value of $48,900.00.

Shares of FibroGen Inc (NASDAQ:FGEN) traded down 1.83% during trading on Friday, reaching $26.75. The company had a trading volume of 300,400 shares. FibroGen Inc has a 12 month low of $14.50 and a 12 month high of $29.00. The firm has a 50 day moving average price of $26.56 and a 200 day moving average price of $23.77. The company’s market cap is $1.87 billion.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The business had revenue of $26.89 million for the quarter, compared to analysts’ expectations of $26.02 million. FibroGen had a negative net margin of 45.93% and a negative return on equity of 40.38%. Analysts predict that FibroGen Inc will post ($1.81) earnings per share for the current year.

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/05/19/kalevi-kurkijarvi-sells-2000-shares-of-fibrogen-inc-fgen-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in FGEN. Vanguard Group Inc. raised its stake in shares of FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock worth $124,409,000 after buying an additional 392,778 shares in the last quarter. BlackRock Inc. raised its stake in shares of FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of FibroGen by 5.7% in the third quarter. BlackRock Fund Advisors now owns 2,170,992 shares of the biopharmaceutical company’s stock worth $44,940,000 after buying an additional 117,858 shares in the last quarter. FMR LLC raised its stake in shares of FibroGen by 10.5% in the first quarter. FMR LLC now owns 1,694,574 shares of the biopharmaceutical company’s stock worth $41,771,000 after buying an additional 161,143 shares in the last quarter. Finally, State Street Corp raised its stake in shares of FibroGen by 11.1% in the first quarter. State Street Corp now owns 1,514,465 shares of the biopharmaceutical company’s stock worth $37,336,000 after buying an additional 150,807 shares in the last quarter. 47.74% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded FibroGen from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a research note on Friday, January 20th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. FibroGen currently has a consensus rating of “Buy” and an average target price of $37.50.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

5 Day Chart for NASDAQ:FGEN

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply